RecruitingNot ApplicableNCT07597005
Red Propolis Supplementation as a Strategy in Chronic Kidney Disease
Red Propolis as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Chronic Kidney Disease
Sponsor
Universidade Federal Fluminense
Enrollment
40 participants
Start Date
Sep 30, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The objective of this study is to evaluate the effects of red propolis on inflammation and oxidative stress in patients with chronic kidney disease on conservative management.
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria1
- patients with CKD stages 3-5 under conservative management
Exclusion Criteria6
- pregnant,
- lactating,
- smoker
- patients using antibiotics and antioxidant supplements in the last three months
- patients with autoimmune and infectious diseases,
- patients with cancer, liver disease, and AIDS
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIETARY_SUPPLEMENTRed Propolis
Participants will receive 200mg of red propolis capsules per day for two months.
OTHERPlacebo Control
Participants will receive 200mg of placebo capsules per day for two months.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07597005
Related Trials
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
NCT06963827158 locations
A Natural History Study of Metabolic Sizing in Health and Disease
NCT053987831 location
An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea
NCT072325371 location
Impact of NMES and HPRO on Recovery After SAH- Pilot Study
NCT032010941 location
Adia Med of Winter Park LLC Chronic Kidney Disease Research Study
NCT075728901 location